[Correspondence] Efficacy of infliximab biosimilars in patients with Crohn's disease

The study by Kristen K J ørgensen and colleagues1 assessed the efficacy of switching maintenance therapy from originator infliximab to the biosimilar CT-P13 in several inflammatory diseases. Because of the potential effects biosimilars could have on health and the cost of health care, this is an active area of debate.2–4
Source: LANCET - Category: General Medicine Authors: Tags: Correspondence Source Type: research